Medical Devices – U.S. Regulatory Framework
The Food and Drug Administration (FDA) is the authority regulating Medical Devices in the U.S., to ensure their safety and effectiveness. Medical devices are divided into three classes (I, II and III) and this classification defines the regulatory requirements for each device type.
Liliana Teles

Liliana Teles

Regulatory Affairs Manager

MEDICAL DEVICES LEGAL FRAMEWORK IN THE U.S.

All medical devices must comply with the General Controls of the Medical Device Amendments (1976) to the Food, Drug and Cosmetic Act (FD&C Act). General Controls provide the U.S. Food and Drug Administration (FDA) the methods for regulating devices. The FDA’s Center for Devices and Radiological Health (CDRH) is in charge of regulating companies who manufacture, repackage, relabel and/or import medical devices which are sold in the United States (U.S.).

In the General Controls are included provisions concerning: adulteration; misbranding; device registration and listing; premarket notification; banned devices; notification and repair, replacement and refund; records and reports; restricted devices and Good Manufacturing Practices (GMP).

Medical devices are divided in three risk classes (I, II and III). This means that the medical device classification will depend on risk to patient/user, intended use and indications for use. All three classes are subject to the General Controls provisions of the Amendments. Class I medical devices are not intended for use in supporting or sustaining life or to be of substantial importance in preventing impairment to human health. These medical devices may not present a potential unreasonable risk of illness or injury. According to the Amendments, Class I medical devices are the ones which pose the lowest risk.  Class III devices are those with the greatest risk and consequently are most regulated, being subjected to premarket approval (PMA).

For Class I and Class II devices, a 510(k) premarket must be submitted. This submission requires demonstration of a substantial equivalence to another legally marketed device in the U.S. A non-equivalent device must have an approved premarket approval (PMA) application or be reclassified into Class I or Class II before being marketed.

Some medical devices considered Class I and II are exempt from 510(k) requirements), but they must still comply with other requirements (regulatory controls) unless the device is explicitly exempt from those requirements as indicated in the regulation for that device type. A device may be exempt from 510(k) requirements if the FDA determines that a 510(k) is not required to provide reasonable assurance of safety and effectiveness for the device.

Establishments of medical devices manufacturers (and other specified processors) must be registered with the FDA. A list of all the devices manufactured in such establishments must also be provided. The same applies to importers, repackers and relabelers of medical devices.

The FDA may restrict the sale, distribution or use of a medical device if its safety and effectiveness cannot be assured.

INTRODUCING MEDICAL DEVICES IN THE U.S.

Classification of the medical device is the first step for its placement in the U.S. market. Secondly, the company needs to identify the correct premarket submission, which will depend on the medical device classification. For a Class I or Class II device (not exempt), a premarket submission (510(k)) needs to be submitted to FDA to demonstrate that the device is safe and effective, at least 90 days before introducing the device onto the market. It is not possible to commercially distribute the medical device until a letter of substantial equivalence from FDA authorizes it.

When it comes to Class III medical devices, it is mandatory a premarket approval application (PMA), unless there is a preamendments device (on the market prior to the passage of the medical device amendments in 1976, or substantially equivalent to such a device) and PMA’s have not been called for. A 510(k) premarket submission would be the way to go in that case. The PMA process is more complex and includes submission of clinical data to support claims made for the device. A fee must be paid both in 510(k) premarket submission and PMA application.

After documents submission and payment of correspondent fees, the FDA will review the submission and decide on the approval of the medical device, within 90-180 days. Class I and Class II device manufacturers are not inspected by the FDA before device registration. Nevertheless, the FDA may conduct random inspections after registration.

Finally, the medical device establishment must be registered in the FDA and the correspondent fees must be paid. The company and device registration status will be listed on the FDA website and the authorization granted will not expire as long as there are no changes made to the medical device (design, intended use, etc.)

References:

U.S. Food and Drug Administration (FDA) – Overview of Device Regulation – https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/overview-device-regulation

further
reading

cosmetic products

New Formaldehyde Threshold in Cosmetic Products

The European Commission has issued a draft regulation to amend the preamble of Annex V regarding the threshold for labelling formaldehyde releasers. This amendment results from a scientific advice published by the SCCS concluding that the current threshold does not sufficiently protect consumers sensitized to formaldehyde.

Read More »
cosmetic products

New Restriction on the Use of Benzophenone-3 in Cosmetics

Benzophenone-3 was part of a priority list of potential endocrine disruptors established by the European Commission in 2019. The SCCS was asked to assess the safety of this ingredient and the European Cosmetics Regulation will be amended in accordance with the SCCS assessment conclusions.

Read More »
endocrine disruptors
cosmetic products

European Commission Calls for Data on Ingredients with Potential Endocrine-Disrupting Properties

Substances classified as endocrine disruptors are compounds that can alter the functioning of the endocrine system and negatively affect the health of humans and animals. In 2019, the European Commission set out two lists of ingredients suspected of having endocrine disrupting properties. More recently, the Commission has published a call for data for 10 ingredients that were included in the low priority group (Group B) for the SCCS to be able to assess their safety.

Read More »
cosmetic products

SCCS Preliminary Opinion on Prostaglandins and Prostaglandin-analogues

Following the mandate from the European Commission, the Scientific Committee on Consumer Safety (SCCS) has published a preliminary opinion on Prostaglandins and Prostaglandin-analogues used in cosmetic products. This preliminary opinion is open for comments and the deadline was set for 23 november 2021.

Read More »
cosmetic products

SCCS Preliminary Opinion on Butylated Hydroxytoluene (BHT)

Following the mandate from the European Commission, the Scientific Committee on Consumer Safety (SCCS) has published a preliminary opinion on Butylated Hydroxytoluene (BHT). This preliminary opinion is open for comments and the deadline was set for 23 november 2021.

Read More »
cosmetic products

EU Prohibition of Zinc Pyrithione in Cosmetic Products

Zinc Pyrithione has been used for more than 60 years as an anti-dandruff agent in cosmetic products. Last month, the European Commission published the Commission Regulation (EU) 2021/1092, which includes this ingredient in Annex II. From March 2022 onwards, Zinc Pyrithione will be prohibited in cosmetic products.

Read More »
medical devices

EUDAMED Status Update 2021

The development and deployment of EUDAMED is progressing. Following the implementation plan and getting familiar with the information stored in the database’s modules is crucial for economic operators compliance in the EU market.

Read More »
cosmetic products

EU Chemicals Strategy for Sustainability

The Chemicals Strategy for Sustainability (CSS) was recently published by the European Union. The CSS is part of the European Green Deal which aims for a toxic-free environment leading to zero pollution. The initiative proposes a new legislative amend to the EU Cosmetic Products Regulation. Simplification and digitalization of labelling requirements plus review of the definition of nanomaterial are two of the main objectives of the CSS.

Read More »
cosmetic products

Nanotechnology in Sun Care Products

Nanomaterials are increasingly used in cosmetics and personal care products. They are similar to other chemicals/substances, but with specific risks associated to their use. Currently, there are 4 nano-ingredients approved in the European Union for use as UV filters in cosmetic products.

Read More »
cosmetic products

May Butylphenyl Methylpropional be used in Cosmetic Products?

Butylphenyl Methylpropional, also known as Lilial, is a fragrance ingredient that has been used for years in several cosmetic and non-cosmetic products. Nevertheless, some concerns have been expressed regarding the use of this ingredient and its risk to consumers. According to an amendment to the CLP Regulation, the use of Butylphenyl Methylpropional will be prohibited in cosmetic products from 1st March 2022.

Read More »
cosmetic products

How are Cosmetic Products Regulated in the United Arab Emirates?

The United Arab Emirates (UAE) are an emerging market for the beauty industry. Cosmetics and personal care products supplied or sold in the UAE must comply with the health and safety requirements set out in UAE legislation. Overall, the process for importing a cosmetic product into the UAE market from the European Union can be quite straightforward since the UAE has aligned several of its requirements with the European Cosmetic Regulation.

Read More »